On March 28, 2024, Shenzhen Beike Biotechnology Co., Ltd. (hereinafter referred to as Beike Biotechnology) and Beijing Yiqiao Shenzhou Technology Co., Ltd. (hereinafter referred to as Yiqiao Shenzhou, stock code 301047) officially signed a strategic cooperation agreement in Shenzhen. The two parties will carry out in-depth cooperation in the research and scientific research services of stem cells, immune cells, and organoid culture reagents, and jointly commit to breakthroughs in the research and development of high-quality biological reagents and technological research in the fields of stem cells, immune cells, and organoids. In the future, both parties will work together to empower each other, give full play to their respective advantages in resources, capital, technology and management, and jointly promote the development of the cell industry. Dr. Hu Junyuan, chairman of Beike Biotech, and Dr. Zhang Jie, general manager of Yiqiao China, attended the signing ceremony.
Yiqiao Shenzhou is a domestic expert in protein and antibody R&D and production, focusing on providing comprehensive, high-quality recombinant proteins and antibodies and other biological reagents and professional, one-stop technical services for the fields of life science research and innovative drug research and development. Beike Biotechnology is a national high-tech enterprise specializing in the clinical transformation and technical services of biotherapeutic technologies in strategic emerging industries. It has a professional technical R&D team led by many expert scholars with outstanding achievements in the cell field.
This strategic cooperation combines the technical strength of Beike Biotech in the fields of basic cell research and clinical transformation of biotherapeutic technologies with the R&D capabilities and large-scale production capabilities of Yiqiao Shenzhou in the field of biological reagents. Combining the core scientific research advantages of both parties, we will work together to break through the core technology “stuck” problem in the research and development of high-quality biological reagents in fields such as stem cells, immune cells, and organoids. We will jointly develop more high-quality products and services to meet the market demand for basic scientific research and clinical applications, and jointly promote the development of global life and health.